NASDAQ : ACAD
Acadia Pharmaceuticals Inc. (ACAD)Healthcare : Biotechnology$19,80
+0.68 (+3.56%) today
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Open
$19,33
High
$19,84
Low
$19,11
Mkt. cap
3.41B
Avg. vol.
1.83M
Volume
1.30M
52-wk high
$30,96
52-wk low
$18,39
Shares outstanding
172.31M
defenseworld.net - 19 Oct 2026 08:07
ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report)'s stock had its "buy" rating reiss...
prnewswire.com - 15 Oct 2026 10:00
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of...
globenewswire.com - 13 Oct 2026 17:08
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behal...
zacks.com - 13 Oct 2026 11:06
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and ...
defenseworld.net - 12 Oct 2026 02:15
C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD ...
zacks.com - 09 Oct 2026 11:31
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with g...
prnewswire.com - 08 Oct 2026 10:00
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of ...
globenewswire.com - 06 Oct 2026 17:02
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behal...
prnewswire.com - 01 Oct 2026 10:00
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of ...
globenewswire.com - 29 Sep 2026 17:29
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on beha...
Latest reported earnings
Q2 2026
Report date: Aug 4, 2026
EPS / Est.
$0.18 / $0.068
+164.12% beat
Revenue / Est.
$307.96M / $296.55M
+3.85% beat
Past earnings
| Fiscal period | Report date | EPS / Est. | Revenue / Est. |
|---|---|---|---|
| Q1 2026 | May 6, 2026 | $0.02 / $0.04 (-50.00% miss) | $268.10M / $280.25M (-4.34% miss) |
| Q4 2025 | Feb 25, 2026 | $1.6 / $0.137 (+1067.88% beat) | $283.99M / $292.79M (-3.00% miss) |
| Q3 2025 | Nov 5, 2025 | $0.42 / $0.14 (+200.00% beat) | $278.63M / $276.54M (+0.76% beat) |
| Q2 2025 | Aug 6, 2025 | $0.16 / $0.14 (+14.29% beat) | $264.57M / $262.00M (+0.98% beat) |
| Q1 2025 | May 7, 2025 | $0.11 / $0.1 (+10.00% beat) | $244.32M / $238.97M (+2.24% beat) |
| Q4 2024 | Feb 26, 2025 | $0.86 / $0.19 (+352.63% beat) | $259.60M / $255.61M (+1.56% beat) |
| Q3 2024 | Nov 6, 2024 | $0.2 / $0.14 (+42.86% beat) | $250.40M / $282.92M (-11.49% miss) |
| Q2 2024 | Aug 6, 2024 | $0.2 / $0.18 (+11.11% beat) | $241.96M / $235.42M (+2.78% beat) |
| Q1 2024 | May 8, 2024 | $0.1 / $0.05 (+100.00% beat) | $205.83M / $208.29M (-1.18% miss) |
| Q4 2023 | Feb 27, 2024 | $0.28 / $0.3 (-6.67% miss) | $231.04M / $223.78M (+3.24% beat) |
| Q3 2023 | Nov 2, 2023 | $-0.4 / $-0.43 (+6.98% beat) | $211.70M / $224.38M (-5.65% miss) |
| Q2 2023 | Aug 2, 2023 | $0.01 / $-0.12 (+108.33% beat) | $165.24M / $157.85M (+4.68% beat) |
Catherine E. Owen Adams - CEO
Allyson McMillan Youngblood - Senior Vice President of Rare Disease Franchise
Catherine E. Owen Adams - Chief Executive Officer & Director
Jennifer J. Rhodes - Executive Vice President, Chief Legal Officer & Secretary
Elizabeth Thompson - Executive Vice President and Head of Research & Development
Albert S. Kildani - Senior Vice President of Investor Relations & Corporate Communications
Carl Segerstrom - Chief People Officer
James K. Kihara - Senior Vice President of Finance
Mark C. Schneyer - Executive Vice President & Chief Financial Officer
Scott Cenci - Senior Vice President, Chief Information & Data Officer
Thomas Andrew Garner - Executive Vice President & Chief Commercial Officer